semaglutide fatty liver disease 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Once-Weekly Subcutaneous Semaglutide Improves Fatty

In a survey, employers told the Business Group on Health that they arent yet seeing evidence of long-term health benefits from taking GLP-1s for weight loss, leaving them unsure how to manage costs while continuing to cover them.

Given this patient's uncontrolled diabetes, high cardiovascular and renal risk, and concurrent use of ramipril (an ACE inhibitor), celecoxib 200mg should be ...

Mounjaro and Ozempic both help control blood sugar and promote weight loss in people with diabetes

Establishing cardiovascular safety of new therapies for type 2 diabetes is important

Little is known about the association of discontinuation of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RA) with outcomes in patients with CKD

Jetzt lesen.